A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine

Inclusion Criteria Concurrent Medication: Allowed: * Concomitant medications for the treatment of complications of AIDS. * CAUTION: * Concomitant use of ddI with the following drugs must be done with extreme caution: * Other nucleosides (e.g., ganciclovir). * Drugs with toxicities similar to those observed with ddI (e.g., phenytoin). * Drugs with significant pancreatic toxicities, including many drugs used for treatment of major opportunistic infections. * Use of Sulfonamides or intravenous pentamidine for treatment of acute Pneumocystis carinii pneumonia (PCP) requires discontinuation of ddI for a week following treatment of PCP. * Caution should also be exercised with patients having intractable diarrhea or patients following a low sodium diet. Patients must have the following: \- Diagnosis of AIDS. Demonstrated either significant deterioration despite parenteral dosing with zidovudine (AZT) or significant intolerance to AZT. Signed informed consent by parent or legal guardian. Evaluations every 7-14 days while taking ddI for the first 4 months. Monthly follow-up is required thereafter. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Acute pancreatitis or any history of pancreatitis. * Seizures or a history of seizure disorder. * Grade I or greater peripheral neuropathy. * Preexisting cardiomyopathy. Concurrent Medication: Excluded: * Zidovudine (AZT). * Chemotherapy with cytotoxic agents. * AVOID: * Those agents that may cause pancreatitis such as: * Pentamidine. * Sulfonamides. * Antituberculosis drugs. * Cimetidine. * Ranitidine. * Corticosteroids. * NOTE the cautionary statement in Patient Inclusion Concurrent Medication. Patients with the following are excluded: * Acute pancreatitis or any history of pancreatitis. * Seizures or a history of seizure disorder. * Grade I or greater peripheral neuropathy. * Preexisting cardiomyopathy. Prior Medication: Excluded within 15 days of study entry: * Any anti-retroviral except zidovudine (AZT). Required: * Zidovudine (AZT).